6
29th CINP World
Congress 2014
Monday, 23 June 2014
09:00–09:45 PL-1
The Arvid Carlsson Lecture: The ups and downs of amphetamines:
A diversity of actions on cellular signaling pathways
10:00–11:00 W-1 The pitfalls, problems using gene knockout animals in neuropsychopharmacology (Scientific)
10:00–12:00
S-1 Remodeling the neurocircuitry of depression: Ketamine and glutamate
S-2
Neuron-glia interaction in schizophrenia: Focus on D-serine
S-3
Developing novel drug classes for bipolar disorder
S-4
Paediatric disorders characterised by aggression and/or social impairment:
from preclinical research to clinical subtyping
S-5
Alcohol dependence: Neuroimaging and pharmacology
JS-1 Japanese Session
11:10–12:10 W-2
The use of psychotropic drugs during pregnancy and breast feeding (Educational)
12:15–13:45
Industry Satellite Symposia
14:00–14:45 PL-2 Nobel Lecture: Structural insights into G protein coupled receptor signaling
15:00–16:00 W-3 Managing treatment resistance in psychiatry (Educational)
15:00–16:30 P/C-1 Lithium is no longer needed as a mood stabiliser
15:00–17:00
S-6 Emerging neuromechanisms for the treatment of depression: Insights from animal and human studies
S-7
Allosteric modulators of metabotropic glutamate receptors (mGlu) as novel tools for the treatment
of CNS disorders
S-8 Obsessive-compulsive and related disorders: A translational approach
S-9 Neuroimaging vulnerability to neuropsychiatric disorders
S-10 Coming of age for phosphodiesterase inhibitors as central nervous system therapeutics
16:10–17:10 W-4 GPCRs and psychotherapeutic drug development (Scientific)
Tuesday, 24 June 2014
09:00–09:45 PL-3 The importance of being an endocannabinoid
10:00–12:00
S-11 The potential of high-risk studies to inform early intervention in bipolar disorder
S-12 Targeting the endocannabinoid system to treat psychiatric disorder: Clinical and pre-clinical evidence
S-13
The epigenetic embedding of early life stress in humans and animal models
S-14 Prefrontal norepinephrine in arousal and executive function
S-15 BACE1 in Alzheimer’s disease pathogenesis and drug development
10:00–11:00 W-5
Understanding modern genetics (Educational)
10:00–12:00 KS-1 Korean Session
11:10–12:10 W-6 Optimising drug trial design (Educational)
12:15–13:45
Industry Satellite Symposia
14:00–14:45 PL-4 Brain science using ips cell technology and transgenic non-human primates
15:00–16:30 P/C-2 DSM5 will be the Death of Psychopharmacology
15:00–17:00
S-16 New basic and clinical developments for treatment resistant depression
S-17
Novel glutamatergic treatment approaches for schizophrenia: Pharmacology, imaging and clinical trials
S-18
Breakthroughs in psychopharmacology for prevention and treatment of PTSD
S-19
The psychopharmacology of aggression: From biomarkers to therapeutics
S-20
Remodeling synaptic connections in the pathophysiology and treatment of depression
15:00–16:00 W-7
Treatment of ADHD across the lifespan (Educational)
16:10–17:10 W-8 Translating schizophrenia to animal models: What works and what doesn’t (Educational)
Preliminary scientific overview
18:00–21:30
Opening Ceremony and Welcome Reception
Sunday, 22 June 2014
